Globus Medical (NYSE:GMED) Announces Quarterly Earnings Results

Posted by on Aug 8th, 2026

Globus Medical (NYSE:GMED – Get Free Report) announced its earnings results on Thursday. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24, FiscalAI reports. The firm had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the company posted $0.86 EPS. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

  • Positive Sentiment: Q2 revenue rose 5.9% to $789.6 million, while base-business revenue excluding Nevro increased 9%; adjusted EPS jumped 56% to a record $1.34.
  • Positive Sentiment: U.S. spine grew 7%, international spine rose 14% as reported, and trauma increased 31%, supported by new products, competitive sales-force recruiting, improved inventory availability, and continued market-share gains.
  • Positive Sentiment: Adjusted gross margin expanded 200 basis points to 69.4% and adjusted EBITDA margin reached 35.4%; management raised 2026 non-GAAP EPS guidance to $4.95-$5.05 while maintaining revenue guidance of $3.18-$3.22 billion.
  • Negative Sentiment: Nevro sales declined 14.3% year over year and fell sequentially, while enabling-technology revenue dropped 25.8% as the company shifts toward leasing and other flexible capital-acquisition models. Management expects Nevro trial volumes to recover by late Q4, but identified both businesses as risks to second-half revenue.
  • Positive Sentiment: Globus repurchased $136.1 million of shares in Q2 and has $253.9 million remaining under its authorization; it also expects to launch patient-specific SCRIPT lumbar spacers and rods in Q3, adding to a pipeline of more than 60 development projects.

Globus Medical Trading Up 1.4%

Shares of NYSE GMED traded up $1.12 during midday trading on Friday, reaching $82.20. The company’s stock had a trading volume of 3,299,652 shares, compared to its average volume of 1,551,427. Globus Medical has a fifty-two week low of $54.15 and a fifty-two week high of $101.40. The stock has a market capitalization of $11.16 billion, a price-to-earnings ratio of 21.02, a PEG ratio of 1.67 and a beta of 0.95. The stock has a 50 day simple moving average of $79.33 and a 200-day simple moving average of $85.23.

Analyst Upgrades and Downgrades

GMED has been the topic of a number of research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Piper Sandler reduced their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Stifel Nicolaus lowered their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Truist Financial dropped their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Finally, BMO Capital Markets assumed coverage on Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $101.77.

Check Out Our Latest Stock Analysis on GMED

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

  • Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
  • Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
  • Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
  • Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
  • Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Insider Activity at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 18.38% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. grew its holdings in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after acquiring an additional 3,595,339 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Globus Medical by 87.4% during the fourth quarter. Corient Private Wealth LLC now owns 89,916 shares of the medical device company’s stock worth $7,851,000 after acquiring an additional 41,934 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Globus Medical during the fourth quarter worth about $499,000. EP Wealth Advisors LLC acquired a new position in Globus Medical during the fourth quarter valued at approximately $607,000. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Globus Medical during the fourth quarter valued at approximately $90,411,000. 95.16% of the stock is owned by institutional investors.

Globus Medical Company Profile

(Get Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Featured Stories

Earnings History for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.